Literature DB >> 23728452

Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma.

Mi-Seon Shin1, Ji Hee Yu, Jong Han Choi, Chang Hee Jung, Jenie Yoonoo Hwang, Young Hyun Cho, Chang Jin Kim, Min-Seon Kim.   

Abstract

BACKGROUND: Successful treatment of acromegaly is known to normalize serum insulin-like growth factor 1 (IGF-1) levels within days after surgery. However, our clinical observations indicate that many cases of acromegaly show delayed normalization of serum IGF-1 levels after complete tumor resection.
OBJECTIVE: To study long-term changes of the serum IGF-1 levels in acromegalic patients for whom surgical treatment was thought to be successful.
METHODS: A retrospective observational study was performed with 46 acromegalic patients with no residual tumor on sellar magnetic resonance imaging, and a nadir growth hormone of less than 0.4 μg/L on a postoperative oral glucose tolerance test.
RESULTS: In all patients, serum IGF-1 levels returned to the normal reference values for age and sex during the observational period (12-132 months). The mean duration from the time of surgery until IGF-1 normalization was 10 months (range, 3 days-57 months). Twenty-seven patients (59%) reached normal IGF-1 ranges within 3 months of surgery, whereas 19 patients (41%) experienced delayed (>3 months) IGF-1 normalization. Eleven patients (24%) recovered normal IGF-1 levels 12 to 57 months after surgery. The possibility of delayed IGF-1 cure was increased 8.8-fold with an immediate postoperative IGF-1 level increase of 100 μg/L.
CONCLUSION: Satisfactory remission of acromegaly by IGF-1 criteria was delayed in a large proportion of acromegalic patients, especially those with high postoperative IGF-1 levels. Hence, additional treatment can be delayed in clinically stable acromegalic patients who show no evidence of residual tumors on postoperative magnetic resonance imaging and a normal growth hormone suppressive response to a glucose load.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23728452     DOI: 10.1227/01.neu.0000431480.87160.84

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  8 in total

1.  Random Gh and Igf-I levels after transsphenoidal surgery for acromegaly: relation with long-term remission.

Authors:  Marcelo Lemos Vieira da Cunha; Luis Alencar Biurrum Borba; Cesar Luiz Boguszewski
Journal:  Endocrine       Date:  2020-02-20       Impact factor: 3.633

2.  Cost-effectiveness analysis of two therapeutic schemes in the treatment of acromegaly: a retrospective study of 168 cases.

Authors:  L Duan; M Huang; H Yan; Y Zhang; F Gu
Journal:  J Endocrinol Invest       Date:  2015-03-18       Impact factor: 4.256

Review 3.  Current best practice in the management of patients after pituitary surgery.

Authors:  Alessandro Prete; Salvatore Maria Corsello; Roberto Salvatori
Journal:  Ther Adv Endocrinol Metab       Date:  2017-03-01       Impact factor: 3.565

4.  Predictors of postoperative biochemical remission in lower Knosp grade growth hormone-secreting pituitary adenomas: a large single center study.

Authors:  S Zhang; J Chen; Y Zhu; H Wang; Z Mao; S Yao; F Akter; Z Wang; B Hu; D Zhu; C Duan; W Chen
Journal:  J Endocrinol Invest       Date:  2022-09-20       Impact factor: 5.467

5.  Early postoperative prediction of both disease remission and long-term disease control in acromegaly using the oral glucose tolerance test.

Authors:  Kiyohiko Sakata; Yui Nagata; Nobuyuki Takeshige; Jin Kikuchi; Masato Shikata; Kenji Ashida; Masatoshi Nomura; Motohiro Morioka
Journal:  Hormones (Athens)       Date:  2021-03-18       Impact factor: 2.885

6.  Microsurgical resection of foramen magnum meningioma: multi-institutional retrospective case series and proposed surgical risk scoring system.

Authors:  Nida Fatima; John H Shin; William T Curry; Steven D Chang; Antonio Meola
Journal:  J Neurooncol       Date:  2021-05-10       Impact factor: 4.130

Review 7.  A Consensus Statement on acromegaly therapeutic outcomes.

Authors:  Shlomo Melmed; Marcello D Bronstein; Philippe Chanson; Anne Klibanski; Felipe F Casanueva; John A H Wass; Christian J Strasburger; Anton Luger; David R Clemmons; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2018-09       Impact factor: 43.330

Review 8.  Need for improved monitoring in patients with acromegaly.

Authors:  Julie M Silverstein
Journal:  Endocr Connect       Date:  2015-09-17       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.